Achieved record full-year revenue and EBITDA driven by durable demand in markets growing 2x to 3x faster than the national average.

Successfully stabilized third-quarter headwinds in professional fees and payer denials through strategic recontracting and revenue cycle partnerships.

Executed precision staffing and optimized operating room workflows, resulting in a 26% reduction in contract labor expenses during the fourth quarter.

Expanded the IMPACT program to a $55 million savings target for 2026, focusing on multiyear structural agility and care transformation.

Utilized a single-instance Epic platform to standardize clinical workflows and drive top-quartile performance in quality and safety metrics.

Accelerated AI adoption, with AI-enhanced scribes now used in approximately 85% of patient visits to improve documentation quality and revenue capture.

Established a 2026 EBITDA guidance range of $485 million to $535 million, incorporating a $50 million headwind from annualized professional fees and rate pressures.

Assumes a prudent $35 million headwind from potential exchange disruption, modeling a 20% decline in enrollment following the expiration of enhanced subsidies.

Expects adjusted admissions growth of 1.5% to 2.5%, supported by rising care complexity and strong market positioning.

Anticipates a return to adjusted EBITDA growth in 2027 as the company laps 2025 headwinds and IMPACT program savings fully materialize.

Plans an enterprise-wide rollout of AI-assisted virtual care to over 2,000 patient rooms by year-end to enhance clinical talent utilization.

Operating cash flow increased 49% in 2025, though management flags a $50 million headwind in 2026 due to the timing of the final payroll cycle.

Reduced lease-adjusted net leverage by nearly 0.5 turn to 2.5x, providing flexibility for disciplined capital deployment through market cycles.

Guidance excludes potential upside from the Rural Health Fund, despite management's belief that approximately 1/3 of their hospitals may qualify.

Restoration of short-term incentive compensation to typical baseline targets creates a $20 million year-over-year impact on the 2026 EBITDA bridge.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Management assumes approximately 10% to 15% of disenrolled exchange members will move to employer-sponsored coverage, while the remainder shift to self-pay.

Utilization for the affected cohort is expected to be roughly 30% lower than previous levels.

The $55 million target for 2026 is considered fully identified, with the majority of incremental savings coming from salaries, wages, and benefits.

Management expects a modest ramp of these savings into 2027, supplemented by new opportunities in supply chain and revenue cycle management.

Ardent is roughly 90% contracted for 2026, with commercial rate increases trending between 4% and 5%.

Core earnings growth of 4% is supported by these rate increases and volume-based supplemental payment programs in growing states.

Winter Storm Heather impacted Texas and Oklahoma markets in January, but management noted that lost volumes largely returned in February.

The overall impact on Q1 is expected to be immaterial and not an enduring dynamic.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.